|Last Price$9.19||Day Change (%)-1.29%|
|Open Price$9.24||Day Change ($)-0.12|
|Day Range9.03–9.28||52-Week Range6.00–13.18|
As of Fri 10/21/2016 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.